H.R. 672: Prescription Drug Abuse Prevention and Treatment Act of 2013

Introduced:
Feb 13, 2013 (113th Congress, 2013–2015)
Sponsor:
Rep. Nick Rahall II [D-WV3]
Status:
Referred to Committee
See Instead:

S. 348 (same title)
Referred to Committee — Feb 14, 2013

The bill’s title was written by the bill’s sponsor. H.R. stands for House of Representatives bill.

Track this bill
(About Ads | Advertise Here)
Status

This bill was assigned to a congressional committee on February 13, 2013, which will consider it before possibly sending it on to the House or Senate as a whole.

Progress
Introduced Feb 13, 2013
Referred to Committee Feb 13, 2013
Reported by Committee ...
Passed House ...
Passed Senate ...
Signed by the President ...
Prognosis

1% chance of getting past committee.
0% chance of being enacted.

Only 11% of House bills made it past committee and only 3% were enacted in 2011–2013. [show factors | methodology]

Cosponsors
none
Committees

House Energy and Commerce

↪ Health

House Judiciary

↪ Crime, Terrorism, Homeland Security, and Investigations

The committee chair determines whether a bill will move past the committee stage.

Full Title

To provide for increased Federal oversight of prescription opioid treatment and assistance to States in reducing opioid abuse, diversion, and deaths.

Summary

No summaries available.

Text

Read Bill Text »

Last updated Feb 13, 2013.
23 pages

Primary Source

View on THOMAS (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here.

Citation

Click a format for a citation suggestion:

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

2/13/2013--Introduced.
Prescription Drug Abuse Prevention and Treatment Act of 2013 - Amends the Public Health Service Act to direct the Administrator of the Substance Abuse and Mental Health Services Administration to award grants to states and nonprofit entities for consumer education about opioid abuse, including methadone abuse.
Amends the Controlled Substances Act to:
(1) set forth training requirements for practitioners registered to prescribe or dispense methadone or other opioids, and
(2) require each registered opioid treatment clinic to make acceptable arrangements for each patient who is restricted from having a take-home dose of a controlled substance related to treatment to receive a dose of that substance under appropriate supervision when the clinic is closed.
Prohibits any individual or entity (except hospitals that provide direct patient supervision) from prescribing or dispensing a 40-mg diskette of methadone unless such prescription or dispensation is consistent with the current Drug Enforcement Administration (DEA) methadone policy, until the date the Controlled Substances Clinical Standards Commission:
(1) publishes dosing guidelines for methadone, and
(2) finds that such 40-mg diskettes are safe and clinically appropriate.
Requires the Secretary of Health and Human Services (HHS) to establish such Commission to develop and publish guidelines related to methadone use, including safe dosing guidelines for all forms of methadone and benchmark guidelines for the reduction of methadone abuse.
Requires states receiving controlled substances monitoring program grants to:
(1) provide information, upon request, to drug enforcement officials relating to an individual who is the subject of an active drug-related investigation; and
(2) require opioid-related deaths to be reported to the Administrator. Directs the Administrator to develop a Model Opioid Treatment Program Mortality Report. Requires the Administrator to establish and implement, through the National Center for Health Statistics, a National Opioid Death Registry to track opioid-related deaths.
Requires the Secretary, acting through the Director of the Agency for Healthcare Research and Quality (AHRQ), to require the development and application of specific prescription drug abuse prevention and treatment quality measures for each relevant health care provider setting.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

The bill contains the following citations to other parts of U.S. law:

United States Code

The United States Code is the compilation of permanent laws enacted by Congress. Temporary and other non-permanent laws do not appear in the United States Code. (About half of the United States Code is the law itself, called positive law. The other half is merely a compilation of the laws but has no legal significance.)